Enanta Pharmaceuticals's top three insider shareholders as of August 29, 2026 are Jay R. Luly (President And Ceo, 871.87K shares), Jay R. Luly (President And Ceo, 871.87K shares), Yat Sun Or (Chief Scientific Officer, 374.85K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jay R. Luly | President And Ceo | 871,871 | 0 | 871,871 | 54.9% | 13 Feb, 2026 |
| 2 | Yat Sun Or | Chief Scientific Officer | 374,854 | 0 | 374,854 | 23.6% | 13 Feb, 2026 |
| 3 | Paul J Mellett | Chief Fin. Admin Officer | 95,884 | 0 | 95,884 | 6.0% | 14 Feb, 2025 |
| 4 | Nathaniel S. Gardiner | Chief Legal Officer | 75,688 | 0 | 75,688 | 4.8% | 27 Feb, 2024 |
| 5 | Brendan Luu | Chief Business Officer | 41,634 | 0 | 41,634 | 2.6% | 13 Feb, 2026 |
| 6 | Nathalie Adda | Sr. Vp Chief Medical Officer | 34,982 | 0 | 34,982 | 2.2% | 05 Apr, 2022 |
| 7 | Tara Lynn Kieffer | Chief Product Strategy Officer | 33,925 | 0 | 33,925 | 2.1% | 13 Feb, 2026 |
| 8 | Scott T. Rottinghaus | Chief Medical Officer | 23,787 | 0 | 23,787 | 1.5% | 10 Aug, 2026 |
| 9 | Harry R. Iii Trout | Officer | 16,348 | 0 | 16,348 | 1.0% | 05 Dec, 2025 |
| 10 | Kathleen S. Capps | Officer | 8,377 | 0 | 8,377 | 0.5% | 05 Dec, 2025 |
| 11 | Terry Vance | Director | 5,800 | 0 | 5,800 | 0.4% | 15 Dec, 2023 |
| 12 | Matthew Paul Kowalsky | Chief Legal Officer | 3,591 | 0 | 3,591 | 0.2% | 13 Feb, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 08 Aug, 2026 | Scott T. Rottinghaus | Chief Medical Officer | Disposed F | 1,467 | $13.34 | $19.57K | 23,787 | Direct |
| 11 Mar, 2026 | Terry Vance | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Yujiro S Hata | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Terry Vance | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Terry Vance | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Terry Vance | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Bruce L A Carter | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Lesley Russell | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Lesley Russell | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 11 Mar, 2026 | Kristine Peterson | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 12 Feb, 2026 | Yat Sun Or | Chief Scientific Officer | Acquired A | 1,650 | $0.00 | $0 | 373,042 | Direct |
| 12 Feb, 2026 | Brendan Luu | Chief Business Officer | Acquired A | 1,575 | $0.00 | $0 | 39,904 | Direct |
| 12 Feb, 2026 | Brendan Luu | Chief Business Officer | Acquired A | 1,575 | $0.00 | $0 | 39,904 | Direct |
| 12 Feb, 2026 | Tara Lynn Kieffer | Chief Product Strategy Officer | Acquired A | 1,575 | $0.00 | $0 | 32,195 | Direct |
| 12 Feb, 2026 | Yat Sun Or | Chief Scientific Officer | Acquired A | 1,650 | $0.00 | $0 | 373,042 | Direct |
| 12 Feb, 2026 | Scott T. Rottinghaus | Chief Medical Officer | Acquired A | 1,650 | $0.00 | $0 | 23,442 | Direct |
| 12 Feb, 2026 | Scott T. Rottinghaus | Chief Medical Officer | Acquired A | 1,650 | $0.00 | $0 | 23,442 | Direct |
| 12 Feb, 2026 | Jay R. Luly | President And Ceo | Acquired A | 4,800 | $0.00 | $0 | 862,826 | Direct |
| 12 Feb, 2026 | Brendan Luu | Chief Business Officer | Acquired A | 1,575 | $0.00 | $0 | 39,904 | Direct |
| 12 Feb, 2026 | Tara Lynn Kieffer | Chief Product Strategy Officer | Acquired A | 1,575 | $0.00 | $0 | 32,195 | Direct |